Market research
PANACEABIO.NSE Panacea Biotec Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 21B
- P/E ratio
- Not available
- Analyst target
- 69
- Dividend yield
- Not available
- Beta
- 0.25
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- INE922B01023
- Market cap
- 21B
- P/E ratio
- Not available
- Analyst target
- 69
- Dividend yield
- Not available
- Beta
- 0.25
About
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeutic areas, such as diabetes, gastro-intestinal care, nephrology, oncology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, and Mpox, etc. The company also offers health supplement products; and nutrition products under the ChilRun full, ChilRun 7+, and ChillRun No Sucrose brands. In addition, it engages in the real estate business. It exports its products to approximately 50 countries. It has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PANACEABIO.NSE discussion.
5 years, 6 months ago
Panacea Biotec Limited is currently in a long term uptrend where the price is trading 46.8% above its 200 day moving average.
From a valuation standpoint, the stock is 58.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
Panacea Biotec Limited's total revenue sank by 15.5% to $1B since the same quarter in the previous year.
Its net income has dropped by 87.9% to $-401M since the same quarter in the previous year.
Finally, its free cash flow grew by 153.4% to $338M since the same quarter in the previous year.
Based on the above factors, Panacea Biotec Limited gets an overall score of 3/5.